The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study

Xingli Zhoua Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;b Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaView further author information

Tongying Zhanc West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China;d Department of Dermatology, Women’s and Children’s Hospital Affiliated to Medical, College of Chengdu University of Electronic Science and Technology/Chengdu, Women’s and Children’s Central Hospital, Chengdu, ChinaView further author information

Xiaoxi Xua Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;c West China School of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaView further author information

Tianjiao Lanc West China School of Medicine, West China Hospital, Sichuan University, Chengdu, China;e West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, ChinaView further author information

Hongxiang Hua Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;b Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaView further author information

Yuxi Zhoua Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;b Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaView further author information

Dengmei Xiac West China School of Medicine, West China Hospital, Sichuan University, Chengdu, ChinaView further author information

Jinqiu Wangf Department of Outpatient, West China Hospital, Sichuan University, Chengdu, ChinaView further author information

Yiyi Wanga Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;b Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaView further author information

Yue Xiaoa Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;b Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaView further author information

Wei Lia Department of Dermatology, Rare Diseases Center, West China Hospital, Sichuan University, Chengdu, China;b Laboratory of Dermatology, Clinical Institute of Inflammation and Immunology, Frontiers Science Center for Disease-related Molecular Network, West China Hospital, Sichuan University, Chengdu, ChinaCorrespondence[email protected]
View further author information

show all

The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

The efficacy and safety of low-dose rituximab in the treatment of pemphigus vulgaris: a cohort study

Citations (0)

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date